Table 1.
Pathway enrichments
|
KEGG pathways |
Pik3-cluster |
Runx-cluster |
||
|---|---|---|---|---|
| Rank | p -value | Rank | p -value | |
| Cell cycle |
60 |
0.11 |
1 |
1.7E-10 |
| Prostate cancer |
4 |
1.4E-07 |
2 |
1.3E-08 |
| Chronic myeloid leukemia |
2 |
4.1E-10 |
3 |
3.6E-08 |
| Pathways in cancer |
8 |
3.4E-07 |
4 |
9.2E-08 |
| HTLV-I infection |
28 |
0.001 |
5 |
5.2E-07 |
| Small cell lung cancer |
20 |
4.6E-05 |
6 |
8.9E-07 |
| Colorectal cancer |
14 |
2.1E-06 |
7 |
8.3E-06 |
| Glioma |
3 |
3.1E-08 |
8 |
5.2E-05 |
| p53 signaling pathway |
73 |
0.27 |
9 |
5.3E-05 |
| Transcriptional misregulation in cancer |
77 |
0.36 |
10 |
5.3E-05 |
| T cell receptor signaling pathway |
1 |
1.1E-11 |
35 |
0.47 |
| B cell receptor signaling pathway |
5 |
1.5E-07 |
34 |
0.44 |
| Non-small cell lung cancer |
6 |
1.6E-07 |
13 |
0.0002 |
| Fc epsilon RI signaling pathway |
7 |
3.2E-07 |
65 |
0.95 |
| ErbB signaling pathway |
9 |
7.9E-07 |
21 |
0.05 |
| Pancreatic cancer | 10 | 8.7E-07 | 14 | 0.0003 |
The top ranked pathways of KEGG enrichment analysis for the Runx- and Pik3-cluster determined at the small- and large-scale, respectively (Figure 3A, B).